This page lists the SEC filings reported by BIOMARK CAPITAL FUND IV LP.
Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
---|---|---|---|---|---|---|
SC 13D/A | 2017-01-30 | BIOMARK CAPITAL FUND IV LP | ADMA BIOLOGICS, INC. | 1,473,391 | 11.4% | EDGAR |
SC 13G/A | 2016-02-16 | BIOMARK CAPITAL FUND IV LP | MABVAX THERAPEUTICS HOLDINGS, INC. | 197,641 | 0.7% | EDGAR |
SC 13G/A | 2015-02-10 | BIOMARK CAPITAL FUND IV LP | MABVAX THERAPEUTICS HOLDINGS, INC. | 197,641 | 9.1% | EDGAR |
SC 13G | 2014-07-18 | BIOMARK CAPITAL FUND IV LP | TELIK INC | 1,581,129 | 11.4% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.